Rep. Dwight Evans Sells AbbVie Inc. (NYSE:ABBV) Stock

Representative Dwight Evans (D-Pennsylvania) recently sold shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on April 17th, the Representative disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on April 3rd. The trade occurred in the Representative’s “CETERA” account.

Representative Dwight Evans also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Quanta Services (NYSE:PWR) on 4/3/2025.
• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 4/3/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 4/3/2025.
• Sold $1,001 – $15,000 in shares of NextEra Energy (NYSE:NEE) on 4/3/2025.
• Sold $1,001 – $15,000 in shares of American Tower (NYSE:AMT) on 4/3/2025.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 4/3/2025.
• Sold $1,001 – $15,000 in shares of ONEOK (NYSE:OKE) on 4/3/2025.
• Purchased $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 4/3/2025.
• Sold $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 4/3/2025.
• Sold $1,001 – $15,000 in shares of Kinder Morgan (NYSE:KMI) on 4/3/2025.

AbbVie Trading Up 0.6 %

Shares of ABBV stock opened at $172.78 on Friday. The company has a market cap of $305.64 billion, a price-to-earnings ratio of 71.99, a PEG ratio of 1.62 and a beta of 0.55. AbbVie Inc. has a 1-year low of $153.58 and a 1-year high of $218.66. The stock has a 50 day simple moving average of $198.47 and a 200-day simple moving average of $187.82. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same period in the previous year, the business earned $2.79 earnings per share. On average, equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a yield of 3.80%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie’s dividend payout ratio is currently 273.33%.

Insider Activity

In other news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the business’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $210.08, for a total value of $12,359,426.56. Following the completion of the sale, the executive vice president now directly owns 53,234 shares of the company’s stock, valued at approximately $11,183,398.72. The trade was a 52.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Kevin K. Buckbee sold 18,944 shares of the company’s stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $203.41, for a total value of $3,853,399.04. Following the completion of the sale, the senior vice president now directly owns 11,496 shares of the company’s stock, valued at approximately $2,338,401.36. This trade represents a 62.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 113,471 shares of company stock worth $23,426,451. 0.25% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AbbVie

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP raised its holdings in shares of AbbVie by 35.8% in the 4th quarter. Quantbot Technologies LP now owns 1,047 shares of the company’s stock valued at $186,000 after purchasing an additional 276 shares in the last quarter. Everence Capital Management Inc. raised its stake in AbbVie by 41.3% in the fourth quarter. Everence Capital Management Inc. now owns 53,171 shares of the company’s stock valued at $9,448,000 after buying an additional 15,550 shares in the last quarter. GAMMA Investing LLC raised its stake in AbbVie by 9.5% in the fourth quarter. GAMMA Investing LLC now owns 39,453 shares of the company’s stock valued at $7,011,000 after buying an additional 3,439 shares in the last quarter. Sky Investment Group LLC lifted its holdings in AbbVie by 10.1% during the 4th quarter. Sky Investment Group LLC now owns 42,715 shares of the company’s stock worth $7,590,000 after buying an additional 3,936 shares during the last quarter. Finally, Wedmont Private Capital boosted its position in shares of AbbVie by 16.5% during the 4th quarter. Wedmont Private Capital now owns 25,822 shares of the company’s stock worth $4,523,000 after acquiring an additional 3,654 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent analyst reports. Raymond James restated an “outperform” rating and set a $220.00 price objective (up from $218.00) on shares of AbbVie in a research report on Monday, February 3rd. Guggenheim reiterated a “buy” rating and issued a $214.00 price objective on shares of AbbVie in a report on Thursday. The Goldman Sachs Group reissued a “neutral” rating and set a $194.00 target price on shares of AbbVie in a research note on Tuesday, April 8th. Truist Financial upped their price target on AbbVie from $211.00 to $217.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Finally, Citigroup raised their price objective on AbbVie from $205.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Seven equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $210.71.

About Representative Evans

Dwight Evans (Democratic Party) is a member of the U.S. House, representing Pennsylvania’s 3rd Congressional District. He assumed office on January 3, 2019. His current term ends on January 3, 2027.

Evans (Democratic Party) is running for re-election to the U.S. House to represent Pennsylvania’s 3rd Congressional District. He declared candidacy for the 2026 election.

Evans earned his A.A. from the Community College of Philadelphia in 1973 and his bachelor’s degree from La Salle College in 1975. He then attended Graduate Work at Temple University from 1975 to 1976. His professional experience includes working as an employment counselor/job developer for the Urban League of Philadelphia and as a teacher in the Philadelphia Public School System.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.